Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangzhou, China.

Survival: monthsCountry:China
Toxiciy Grade:5City/State/Province:Guangzhou
Treatments:ChemotherapyHospital:Guangdong Lung Cancer Institute, Guangdong General Hospital
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 3 study involved untreated advanced non-small cell lung cancer patients who were divided into two separate treatment groups. Of the total patient population, 78.5% were female and 82.5% were less than 65 years of age. There were 184 patients in group A and 188 in group B.

Treatment:
Patients in group A were treated with the biologic therapy agent gefitinib, which is an inhibitor of EGFR and interferes with cancer cell growth.

Patients in group B were treated with the chemotherapy agents carboplatin and paclitaxel.

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 diarrhea, rash, and liver toxicity.

There were two treatment-related deaths in group B due to lung infection and pneumonia. Grade 3-4 leukopenia, neutropenia, vomiting, and neurotoxicity were also reported.

Results:
The median overall survival for groups A and B was 18.1 and 18.3 months, respectively.

Support:
This study was supported by AstraZeneca, makers of gefitinib.

Correspondence: Dr. Yi-Long Wu; email: [email protected]



Back